Partial remission in thymic-NET with alpha-PRRT (Ac-225) refractory to beta-PRRT (Y-90/Lu-177)

被引：0

作者：

Singh, Aviral ^{[1
]}

Kulkarni, Harshad R. ^{[1
]}

Kreuzau, Julia ^{[1
]}

Meister, Josephin ^{[1
]}

Robiller, Franz Christoph ^{[1
]}

机构：

[1] Zentralklinik Bad Berka, Clin Nucl Med, Bad Berka, Germany

来源：

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 17卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：39 / 40

页数：2

共 12 条

[1] Renal Clearance in NET-Patients before and after PRRT with Y-90 DOTATATE and Lu-177 DOTATATE
Helms, F.
Felsch, P.
Knapp, W. H.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 37 : S500 - S500
[2] Toxicity of Peptide Receptor Radiotherapy (PRRT) Using the Somatostatin Analogue DOTA-NOC Labelled with Y-90 or Lu-177
Junak, D. Handkiewicz
Baum, R. P.
Jarzak, B.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2005, 32 : S202 - S202
[3] Leukocyte and White Blood Cell Toxicity during longterm Peptide Receptor Radiotherapy (PRRT) using Y-90 and Lu-177 Labelled Somatostatin Analogues
Junak, D. Handkiewicz
Baum, R.
Jarzab, B.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2005, 32 : S100 - S100
[4] Survival benefits and efficacy of peptide receptor radionuclide therapy (PRRT) using Y-90/Lu-177 DOTA-TATE in pancreatic neuroendocrine tumor (pNET)
Prasad, V.
Hoersch, D.
Hommann, M.
Zachert, C.
Baum, R. P.
JOURNAL OF NUCLEAR MEDICINE, 2009, 50
[5] Pancreatic Neuroendocrine Tumor (pNET): Survival Benefits and Efficacy of Peptide Receptor Radionuclide Therapy (PRRT) Using Y-90/Lu-177 DOTA-TATE
Prasad, V
Hoersch, D.
Hommann, M.
Zachert, C.
Baum, R. P.
NEUROENDOCRINOLOGY, 2009, 90 (01) : 132 - 133
[6] Efficacy of 225Ac-DOTATATE Targeted Alpha Therapy in Metastatic Gastroenteropancreatic Neuroendocrine Tumors Stable or Refractory to 177Lu-DOTATATE PRRT
Ballal, S.
Yadav, M.
Bal, C.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S85 - S85
[7] Safety and Therapeutic Efficacy of 225Ac-DOTATATE Targeted Alpha Therapy in Metastatic Gastroenteropancreatic Neuroendocrine Tumors Stable or Refractory to 177Lu-DOTATATE PRRT
Bal, Chandrasekhar
Yadav, Madhav
Ballal, Sanjana
Tripathi, Madhavi
JOURNAL OF NUCLEAR MEDICINE, 2020, 61
[8] Broadening horizons with 225Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to 177Lu-DOTATATE PRRT: first clinical experience on the efficacy and safety
Ballal, Sanjana
Yadav, Madhav Prasad
Bal, Chandrasekhar
Sahoo, Ranjit Kumar
Tripathi, Madhavi
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (04) : 934 - 946
[9] Broadening horizons with 225Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to 177Lu-DOTATATE PRRT: first clinical experience on the efficacy and safety
Sanjana Ballal
Madhav Prasad Yadav
Chandrasekhar Bal
Ranjit Kumar Sahoo
Madhavi Tripathi
European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47 : 934 - 946
[10] Impact of two cycles of peptide receptor radionuclide therapy (PRRT) on renal function as determined by repeated Tc-99m DTPA/GFR measurements: comparison between Y-90 DOTA-TATE and Lu-177 DOTA-TATE
Prasad, V.
Baum, R. P.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 : S325 - S325

← 1 2 →